Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 82, Issue 2, 2012, Pages 340-351

  Hellinger, Éva ^a   Veszelka, Szilvia ^b   Tóth, Andrea E ^b   Walter, Fruzsina ^b   Kittel, Ágnes ^b   Bakk, Mónika Laura ^a   Tihanyi, Károly ^a   Háda, Viktor ^a   Nakagawa, Shinsuke ^c,d   Dinh Ha Duy, Thuy ^c,d   Niwa, Masami ^c,d   Deli, Mária A ^b   Vastag, Monika ^a  

^a GEDEON RICHTER LTD   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c NAGASAKI UNIVERSITY   (Japan)

^d PharmaCo Cell Co Ltd   (Japan)

Author keywords

Blood brain barrier; Brain endothelial cell; MDCK MDR1; P glycoprotein; Surrogate BBB model; VB Caco 2

Indexed keywords

ALDOSTERONE; ATENOLOL; CAFFEINE; CHLOROTHIAZIDE; CIMETIDINE; COLCHICINE; CORTICOSTERONE; DEXAMETHASONE; DIGOXIN; ESTRADIOL; FUROSEMIDE; HYDROCORTISONE; INDOMETACIN; KETOCONAZOLE; LIDOCAINE; LOPERAMIDE; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN; OMEPRAZOLE; PARACETAMOL; PHENAZONE; PHENYTOIN; PROGESTERONE; PROPRANOLOL; QUINIDINE; RANITIDINE; SALICYLIC ACID; THEOBROMINE; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; BRAIN CAPILLARY ENDOTHELIAL CELL BASED BLOOD BRAIN BARRIER PENETRATION MODEL; CELL LINE; CELL STRAIN CACO 2; CELL STRAIN MDCKMDR1; CELL STRAIN VB CACO 2; COCULTURE; COMPARATIVE STUDY; DRUG PENETRATION; ELECTRON MICROSCOPY; EPITHELIAL CELL BASED BLOOD BRAIN BARRIER PENETRATION MODEL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INCUBATION TIME; MORPHOLOGY; MOUSE; NONHUMAN; PERICYTE; RAT; WESTERN BLOTTING;

ANIMALS; ASTROCYTES; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CACO-2 CELLS; CELL LINE; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; P-GLYCOPROTEIN; PERICYTES; PERMEABILITY; RATS; RATS, WISTAR;

EID: 84867848663     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.07.020     Document Type: Article

References (60)

1. S. Ohtsuki, and T. Terasaki Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development Pharm. Res. 24 2007 1745 1758 (Pubitemid 47206624)
2. E.M. del Amo, A. Urtti, and M. Yliperttula Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2 Eur. J. Pharm. Sci. 35 2008 161 174
3. N.J. Abbott, A.A. Patabendige, D.E. Dolman, S.R. Yusof, and D.J. Begley Structure and function of the blood-brain barrier Neurobiol. Dis. 37 2010 13 25
4. International Transporter Consortium, K.M. Giacomini, S.M. Huang, D.J. Tweedie, L.Z. Benet, K.L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K.M. Hillgren, K.A. Hoffmaster, T. Ishikawa, D. Keppler, R.B. Kim, C.A. Lee, M. Niemi, J.W. Polli, Y. Sugiyama, P.W. Swaan, J.A. Ware, S.H. Wright, S.W. Yee, M.J. Zamek-Gliszczynski, and L. Zhang Membrane transporters in drug development Nat. Rev. Drug Discov. 9 2010 215 236
5. M. Hammarlund-Udenaes, M. Fridén, S. Syvänen, and A. Gupta On the rate and extent of drug delivery to the brain Pharm. Res. 25 2008 1737 1750
6. M. Hammarlund-Udenaes Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin. Pharmacol. Toxicol. 106 2010 215 220
7. S. Veszelka, Á. Kittel, and M.A. Deli Tools of modelling blood-brain barrier penetrability K. Tihanyi, M. Vastag, Solubility, Delivery and ADME Problems of Drugs and Drug-Candidates 2011 Bentham Science Publishers Washington 166 188 (Chapter 9)
8. M. Vastag, and G.M. Keser Current in vitro and in silico models of blood-brain barrier penetration: a practical view Curr. Opin. Drug Discov. Dev. 12 2009 115 124
9. L. Di, E.H. Kerns, I.F. Bezar, S.L. Petusky, and Y. Huang Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB J. Pharm. Sci. 98 2009 1980 1991
10. Y. Zhang, C.S. Li, Y. Ye, K. Johnson, J. Poe, S. Johnson, W. Bobrowski, R. Garrido, and C. Madhu Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo blood-brain barrier permeability Drug Metab. Dispos. 34 2006 1935 1943 (Pubitemid 44771724)
11. M. Culot, S. Lundquist, D. Vanuxeem, S. Nion, C. Landry, Y. Delplace, M.P. Dehouck, V. Berezowski, L. Fenart, and R. Cecchelli An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening Toxicol. In Vitro 22 2008 799 811
12. S. Nakagawa, M.A. Deli, H. Kawaguchi, T. Shimizudani, T. Shimono, A. Kittel, K. Tanaka, and M. Niwa A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes Neurochem. Int. 54 2009 253 263
13. M.A. Deli, C.S. Abrahám, Y. Kataoka, and M. Niwa Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology Cell Mol. Neurobiol. 25 2005 59 127 (Pubitemid 40558585)
14. B.B. Weksler, E.A. Subileau, N. Perrière, P. Charneau, K. Holloway, M. Leveque, H. Tricoire-Leignel, A. Nicotra, S. Bourdoulous, P. Turowski, D.K. Male, F. Roux, J. Greenwood, I.A. Romero, and P.O. Couraud Blood-brain barrier-specific properties of a human adult brain endothelial cell line FASEB J. 19 2005 1872 1874 (Pubitemid 41598779)
15. N.J. Abbott, D.E. Dolman, and A.K. Patabendige Assays to predict drug permeation across the blood-brain barrier, and distribution to brain Curr. Drug Metab. 9 2008 901 910
16. M. Gumbleton, and K.L. Audus Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier J. Pharm. Sci. 90 2001 1681 1698 (Pubitemid 33062590)
17. M. Vastag, É. Hellinger, M.L. Bakk, and K. Tihanyi Cell-based models of blood-brain barrier penetration Ther. Deliv. 2 2011 549 553
18. J.H. Lin Drug-drug interaction mediated by inhibition and induction of P-glycoprotein Adv. Drug Deliv. Rev. 55 2003 53 81 (Pubitemid 36082882)
19. A. Ayrton, and P. Morgan Role of transport proteins in drug absorption, distribution and excretion Xenobiotica 31 2001 469 497 (Pubitemid 32826389)
20. D.J. Begley ABC transporters and the blood-brain barrier Curr. Pharm. Des. 10 2004 1295 1312 (Pubitemid 38559749)
21. M.P. Dehouck, S. Méresse, P. Delorme, J.C. Fruchart, and R. Cecchelli An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro J. Neurochem. 54 1990 1798 1801
22. S. Nakagawa, M.A. Deli, S. Nakao, M. Honda, K. Hayashi, R. Nakaoke, Y. Kataoka, and M. Niwa Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells Cell. Mol. Neurobiol. 27 2007 687 694 (Pubitemid 47476613)
23. B. Dehouck, M.P. Dehouck, J.C. Fruchart, and R. Cecchelli Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes J. Cell Biol. 126 1994 465 473 (Pubitemid 24226262)
24. V. Berezowski, C. Landry, M.P. Dehouck, R. Cecchelli, and L. Fenart Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier Brain Res. 1018 2008 1 9 (Pubitemid 38942854)
25. B. El Hafny, O. Chappey, M. Piciotti, M. Debray, B. Boval, and F. Roux Modulation of P-glycoprotein activity by glial factors and retinoic acid in an immortalized rat brain microvessel endothelial cell line Neurosci. Lett. 236 1997 107 111 (Pubitemid 27496232)
26. A. Tóth, S. Veszelka, S. Nakagawa, M. Niwa, and M.A. Deli Patented in vitro blood-brain barrier models in CNS drug discovery Recent Pat. CNS Drug Discov. 6 2011 107 118
27. C.J. Bachmeier, W.J. Trickler, and D.W. Miller Comparison of drug efflux transport kinetics in various blood-brain barrier models Drug Metab. Dispos. 34 2006 998 1003 (Pubitemid 43763757)
28. P. Garberg, M. Ball, N. Borg, R. Cecchelli, L. Fenart, R.D. Hurst, T. Lindmark, A. Mabondzo, J.E. Nilsson, T.J. Raub, D. Stanimirovic, T. Terasaki, J.O. Oberg, and T. Osterberg In vitro models for the blood-brain barrier Toxicol. In Vitro 19 2005 299 334 (Pubitemid 40248750)
29. J.J. Hakkarainen, A.J. Jalkanen, T.M. Kääriäinen, P. Keski-Rahkonen, T. Venäläinen, J. Hokkanen, J. Mönkkönen, M. Suhonen, and M.M. Forsberg Comparison of in vitro cell models in predicting in vivo brain entry of drugs Int. J. Pharm. 402 2010 27 36
30. S.G. Summerfield, A.J. Stevens, L. Cutler, M. del Carmen Osuna, B. Hammond, S.P. Tang, A. Hersey, D.J. Spalding, and P. Jeffrey Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain J. Pharmacol. Exp. Ther. 316 2006 1282 1290 (Pubitemid 43345304)
31. S.G. Summerfield, K. Read, D.J. Begley, T. Obradovic, I.J. Hidalgo, S. Coggon, A.V. Lewis, R.A. Porter, and P. Jeffrey Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction J. Pharmacol. Exp. Ther 322 2007 205 213 (Pubitemid 46956363)
32. A. Reichel Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept Chem. Biodivers. 6 2009 2030 2049
33. C. Hilgendorf, G. Ahlin, A. Seithel, P. Artursson, A.L. Ungell, and J. Karlsson Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines Drug Metab. Dispos. 35 2007 1333 1340 (Pubitemid 47121774)
34. B. Feng, J.L. LaPerle, G. Chang, and M.V. Varma Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state Expert Opin. Drug Metab. Toxicol. 6 2010 939 952
35. H. Kusuhara, and Y. Sugiyama In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney Drug Metab. Pharmacokinet. 24 2009 37 52
36. A. Avdeef High-throughput measurement of permeability profiles H. van de Waterbeemd, H. Lennernas, P. Artursson, Drug Bioavailability. Estimation of Solubility, Permeability, Absorption and Bioavailability 2003 Wiley-VCH Weinheim 46 71
37. Q. Wang, J.D. Rager, K. Weinstein, P.S. Kardos, G.L. Dobson, J. Li, and I.J. Hidalgo Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier Int. J. Pharm. 288 2005 349 359 (Pubitemid 40038588)
38. K.M. Mahar Doan, J.E. Humphreys, L.O. Webster, S.A. Wring, L.J. Shampine, C.J. Serabjit-Singh, K.K. Adkison, and J.W. Polli Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs J. Pharmacol. Exp. Ther. 303 2002 1029 1037 (Pubitemid 35424386)
39. P. Artursson, K. Palm, and K. Luthman Caco-2 monolayers in experimental and theoretical predictions of drug transport Adv. Drug Deliv. Rev. 46 2001 27 43
40. A.L. Ungell Caco-2 replace or refine? Drug Discov. Today: Technol. 1 2004 423 430
41. I. Hubatsch, E.G. Ragnarsson, and P. Artursson Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers Nat. Protoc. 2 2007 2111 2119 (Pubitemid 351565848)
42. E. Hellinger, and M. Vastag Intestinal absorption and models of penetration K. Tihanyi, M. Vastag, Solubility, Delivery and ADME Problems of Drugs and Drug-Candidates 2011 Bentham Science Publishers Washington 86 101 (Chapter 5)
43. C. Lohmann, S. Hüwel, and H.J. Galla Predicting blood-brain barrier permeability of drugs: evaluation of different in vitro assays J. Drug Target. 10 2002 263 276 (Pubitemid 34746308)
44. P. Anderle, E. Niederer, W. Rubas, C. Hilgendorf, H. Spahn-Langguth, H. Wunderli-Allenspach, H.P. Merkle, and P. Langguth P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels J. Pharm. Sci. 87 1998 757 762 (Pubitemid 28268577)
45. I. Behrens, and T. Kissel Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers? Eur. J. Pharm. Sci. 19 2003 433 442 (Pubitemid 36952405)
46. P.V. Balimane, Y.H. Han, and S. Chong Current industrial practices of assessing permeability and P-glycoprotein interaction AAPS J. 8 2006 E1 E13
47. E. Hellinger, M.L. Bakk, P. Pócza, K. Tihanyi, and M. Vastag Drug penetration model of vinblastine-treated Caco-2 cultures Eur. J. Pharm. Sci. 41 2010 96 106
48. R. Evers, M. Kool, A.J. Smith, L. van Deemter, M. de Haas, and P. Borst Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport Br. J. Cancer 83 2000 366 374 (Pubitemid 30453578)
49. B.T. Hawkins, S.M. Ocheltree, K.M. Norwood, and R.D. Egleton Decreased blood-brain barrier permeability to fluorescein in streptozotocin-treated rats Neurosci. Lett. 411 2007 1 5 (Pubitemid 44751936)
50. J.L. Madara Regulation of the movement of solutes across tight junctions Annu. Rev. Physiol. 60 1998 143 159 (Pubitemid 28157868)
51. P.J. Gaillard, and A.G. de Boer Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug Eur. J. Pharm. Sci. 12 2000 95 102
52. G. Krause, L. Winkler, S.L. Mueller, R.F. Haseloff, J. Piontek, and I.E. Blasig Structure and function of claudins Biochim. Biophys. Acta 1778 2008 631 645
53. A.H. Schinkel, E. Wagenaar, L. van Deemter, C.A. Mol, and P. Borst Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A J. Clin. Investig. 96 1995 1698 1705
54. A.H. Schinkel, E. Wagenaar, C.A. Mol, and L. van Deemter P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J. Clin. Investig. 97 1996 2517 2524 (Pubitemid 26187339)
55. H. Kusuhara, H. Suzuki, T. Terasaki, A. Kakee, M. Lemaire, and Y. Sugiyama P-glycoprotein mediates the efflux of quinidine across the blood-brain barrier J. Pharmacol. Exp. Ther. 283 1997 574 580 (Pubitemid 27514613)
56. N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of drug transporter studies on drug discovery and development Pharmacol. Rev. 55 2003 425 461 (Pubitemid 37013212)
57. K.A. Lentz, J.W. Polli, S.A. Wring, J.E. Humphreys, and J.E. Polli Influence of passive permeability on apparent P-glycoprotein kinetics Pharm. Res. 17 2000 1456 1460 (Pubitemid 32217554)
58. X. Liu, B.J. Smith, C. Chen, E. Callegari, S.L. Becker, X. Chen, J. Cianfrogna, A.C. Doran, S.D. Doran, J.P. Gibbs, N. Hosea, J. Liu, F.R. Nelson, M.A. Szewc, and J. Van Deusen Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding J. Pharmacol. Exp. Ther. 313 2005 1254 1262 (Pubitemid 40727030)
59. P. Jeffrey, and S.G. Summerfield Challenges for blood-brain barrier (BBB) screening Xenobiotica 37 2007 1135 1151 (Pubitemid 350041554)
60. M. Fridén, H. Ljungqvist, B. Middleton, U. Bredberg, and M. Hammarlund-Udenaes Improved measurement of drug exposure in the brain using drug-specific correction for residual blood J. Cereb. Blood Flow Metab. 30 2010 150 161